Seven Wall Street Firms Lower Coinbase Targets After Q3 Print
Seven Wall Street firms cut Coinbase price targets after Q3 earnings, citing weak trading fees; the stock fell 6% premarket.
According to FT, Blackstone warned Anthropic about potential lack of investment-grade rating post-IPO, causing stock market drops and AI stock declines.
According to the Financial Times, Blackstone has informed Anthropic that the AI company might not secure an investment-grade credit rating following its initial public offering.
The FT reports that Blackstone cautioned Anthropic it may not be granted an IG rating post-IPO.
Equities fell and AI firms encountered added strain following the FT disclosure that Blackstone warned Anthropic about the possibility of not achieving an investment-grade credit rating after its IPO.
This issue introduces a financial consideration into the AI expenditure discussion. Investors are currently evaluating the expense of achieving AI advancement. The prospect of missing an investment-grade rating prompts inquiries about borrowing costs. Poorer credit quality can result in higher funding expenses and a reduced set of available debt investors.
The market response, with equities declining and Treasury notes rising, suggests a cautionary posture. For AI stocks, attention continues on whether upcoming earnings and cash flow can validate present spending levels. The term "may" is crucial: it indicates a prospective warning about a rating possibility, not an official statement from a credit rating organization.
American stocks continue to face pressure, with Nasdaq indexes showing the largest drops as worries about AI expenditure and funding affect market sentiment.
Dow decreased 489.07 points, a fall of 0.93%, to close at 51,859.18.
S&P 500 declined 144.75 points, dropping 1.87%, to 7,575.64.
Nasdaq Composite fell 802.55 points, a loss of 3.06%, ending at 25,382.18.
Russell 2000 dropped 58.42 points, or 2.04%, reaching 2,800.80.
Nasdaq 100 decreased 1,076.94 points, down 3.66%, to 28,325.57.
The sell-off is widespread, yet technology stays at the core of the strain.
Stocks in AI chips and related infrastructure are suffering significant losses.
The selling activity in AI chip and infrastructure stocks is notably intense. Intel paces the losses with a decline exceeding 30%, and the pressure spreads to memory, connectivity, chip design, and data center providers.
Intel saw a 30.25% decline to $64.22.
Sandisk dropped 13.38% to $1,152.03.
Astera Labs fell 13.41% to $251.49.
Coherent decreased 12.81% to $206.83.
Advanced Micro Devices lost 11.96% to $498.66.
Lumentum declined 11.69% to $812.07.
Arm dropped 11.53% to $202.39.
Credo Technology fell 11.46% to $146.34.
Marvell Technology declined 11.36% to $193.54.
Arista Networks decreased 8.53% to $168.50.
Applied Materials fell 8.08% to $387.58.
Western Digital dropped 8.04% to $363.64.
The scope of the drops is the worry. Intel has its own earnings disappointment, but double-digit losses across numerous associated stocks indicate that investors are reviewing the entire AI industry. Strong demand forecasts provide less reassurance when investors grow stricter about funding costs, profit margins, and the cash flow required to support the expenditure.
For purchasers, a lower price by itself does not create a baseline. The initial action is to decelerate the selling and generate support. Until this occurs, sellers dominate in most of the sector.
Share to
Disclaimer: this article comes from third-party media and is provided for reference only. It does not constitute investment advice. Crypto and other financial products carry significant price volatility risk, so please make your own decisions carefully.
Seven Wall Street firms cut Coinbase price targets after Q3 earnings, citing weak trading fees; the stock fell 6% premarket.
Strategy's Q3 2026 earnings call featured an analyst Q&A with Phong Le and Michael Saylor covering digital credit, STRC, and Bitcoin tokenization.
The Nasdaq Composite fell 5.30% in October, its worst month since March 2025, as technology stocks tumbled.
AstraZeneca shares rose nearly 7% after a Q3 earnings beat and a $1.5B savings plan; cancer drugs powered growth.